摘要:
The invention provides methods of stimulating lipolysis in a mammalian cells and tissues by contacting the cell or tissue with an agonist of a CGRP receptor such as the high affinity CGRP receptor. The agonist may preferentially stimulate the high affinity CGRP receptor compared to the metabolic amylin receptor. Methods for screening for identifying receptor agonists are provided, pharmaceutical compositions comprising such agonists, and therapeutic regimens using such agonists are provided.
摘要:
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
摘要:
A mixture of conjugates in which each conjugate in the mixture comprises a calcitonin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may lower serum calcium levels in a subject by 10, 15 or even 20 percent or more. Moreover, the mixture may be more effective at surviving an in vitro model of intestinal digestion than non-conjugated calcitonin. Furthermore, the mixture may exhibit a higher bioavailability than non-conjugated calcitonin.
摘要:
The present invention relates to novel compositions, in particular to compositions comprising calcitonin or a fragment or conjugate thereof and to methods for preparing such compositions. It also relates to oral formulations comprising the compositions and to shelf stable formulations of calcitonin or a fragment or conjugate thereof.
摘要:
Die Erfindung betrifft Calcitonine und Calcitonin-Derivate, wie sie zur Therapie beispielsweise von Osteoporose, der Paget'schen Krankheit oder der Hypercalcämie eingesetzt werden. Die erfindungsgemäßen Calcitonine und Calcitonin-Derivate zeichnen sich durch eine Verbrückung der in den Positionen 17 und 21 befindlichen Aminosäuren aus. Dabei wird durch geeignete Auswahl der in diesen Positionen befindlichen Aminosäuren ein 18-gliedriger bzw. 19-gliedriger Ring erzeugt. Dieser Ring führt zu einer erhöhten konformationellen Stabilität und einer erhöhten Aktivität des veränderten Calcitonins. Ein besonders geeignetes hCt-Analogon ist das erfindungsgemäße Cyclo 17,21 -[Asp 17 ,Orn 21 ]-hCt mit einer 19-gliedrigen Ringstruktur zwischen den lactamverbrückten Asp 17 und Orn 21 .
摘要:
An improved vaginal preparation for effecting a safe and efficient absorption of a physiologically active peptide, characterized by comprising a physiologically active peptide, a fatty acid ester of sucrose, an organic acid, and a pharmaceutically acceptable carrier.
摘要:
A powder for nasal administration of a peptidic or proteinaceous drug comprising: (i) a sorbefacient comprising a compound having a group represented by general formula (I) in its molecule, (wherein the ring (a) represents a cyclohexane or benzene ring which may be substituted at at least 3-, 4- or 5-position; and n represents an integer of 1 to 3) or a salt thereof, and (ii) a peptidic or proteinaceous drug in a therapeutically effective dose.